STOCK TITAN

Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Adagene Inc. (Nasdaq: ADAG), a clinical-stage biopharmaceutical company, announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference scheduled for September 9-15, 2021. Peter Luo, Co-founder and CEO, will present on September 10, 2021, at 2:00 p.m. Eastern. A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days. Adagene focuses on antibody-based cancer immunotherapies, leveraging its proprietary Dynamic Precision Library platform to meet unmet patient needs.

Positive
  • None.
Negative
  • None.

SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will participate in the Morgan Stanley 19th Annual Global Healthcare Conference to be held virtually September 9-15, 2021.

Details on the presentation and Q&A can be found below:

Date:Friday, September 10, 2021
Time:2:00 p.m. Eastern

A live webcast of the presentation will be accessible in the Investors section of the company’s website at https://www.adagene.com. A webcast replay will be available for at least 30 days.

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody, SAFEbody™, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: https://investor.adagene.com.

Internal Contact:
Ami Knoefler
Adagene
650-739-9952
ir@adagene.com

External Contact:
Bruce Mackle
LifeSci Advisors
646-889-1200
bmackle@lifesciadvisors.com

 


FAQ

When is Adagene's presentation at the Morgan Stanley Global Healthcare Conference?

Adagene's presentation will be on September 10, 2021, at 2:00 p.m. Eastern.

Where can I watch the Adagene presentation webcast?

The webcast can be viewed in the Investors section of Adagene's website.

How long will the Adagene presentation replay be available?

The replay of the Adagene presentation will be available for at least 30 days.

What is Adagene's focus in biopharmaceuticals?

Adagene focuses on developing novel antibody-based cancer immunotherapies using its Dynamic Precision Library platform.

Who is the CEO of Adagene participating in the conference?

The CEO of Adagene participating in the conference is Peter Luo, Ph.D.

Adagene Inc. American Depositary Shares

NASDAQ:ADAG

ADAG Rankings

ADAG Latest News

ADAG Stock Data

79.69M
39.29M
10.66%
25.2%
0.15%
Biotechnology
Healthcare
Link
United States of America
Suzhou